• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏磁共振成像显示,肥厚型心肌病伴阵发性心房颤动患者左心房纤维化负担重。

Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging.

机构信息

Hypertrophic Cardiomyopathy Center of Excellence, Johns Hopkins University, Baltimore, Maryland.

Hypertrophic Cardiomyopathy Center of Excellence, Johns Hopkins University, Baltimore, Maryland; Department of Radiology, Johns Hopkins School of Medicine, Baltimore, Maryland.

出版信息

JACC Clin Electrophysiol. 2019 Mar;5(3):364-375. doi: 10.1016/j.jacep.2018.10.016. Epub 2018 Dec 26.

DOI:10.1016/j.jacep.2018.10.016
PMID:30898240
Abstract

OBJECTIVES

This study hypothesized that paroxysmal atrial fibrillation (PAF) reflects the presence of a more severe cardiac hypertrophic cardiomyopathy (HCM) phenotype.

BACKGROUND

HCM is characterized by myocyte hypertrophy, fibrosis, and a high prevalence of PAF. It is currently unresolved whether atrial fibrillation (AF) is a marker or a mediator of adverse outcomes in HCM.

METHODS

This study retrospectively examined 45 HCM patients who underwent cardiovascular magnetic resonance (CMR) imaging in sinus rhythm. The function of all 4 cardiac chambers was assessed, as well as late gadolinium enhancement (LGE) in the left atrium (LA) and left ventricle (LV), as indicators of fibrosis. A fat-saturated, 3-dimensional inversion recovery-prepared, fast-spoiled, gradient-recalled echo sequence, and the image intensity ratio method were used to measure LA-LGE; LGE in the LV was quantified using a semi-automated threshold technique.

RESULTS

HCM patients (n = 45) were divided into 2 groups (PAF, no AF) based on history of PAF. All HCM patients had LGE in the LA posterior wall. The PAF group (n = 18) had higher LA volume, a lower LA ejection fraction, a lower global peak longitudinal LA strain (PLAS), and a higher amount of LA-LGE compared with the no AF group (n = 27). A modest inverse association was noted between the LA ejection fraction, PLAS, and LA-LGE; a positive association was present between LV-LGE and LA-LGE. The PAF group had lower ejection fractions in the LV, right atrium, and right ventricle compared with those in the no AF group.

CONCLUSIONS

PAF is associated with a greater degree of structural LA remodeling and global myopathy, which suggests a more severe cardiac HCM phenotype.

摘要

目的

本研究假设阵发性心房颤动(PAF)反映了更严重的心脏肥厚型心肌病(HCM)表型的存在。

背景

HCM 的特征是心肌细胞肥大、纤维化以及 PAF 的高发生率。目前尚不清楚心房颤动(AF)是否是 HCM 不良结局的标志物或介质。

方法

本研究回顾性检查了 45 例在窦性心律下接受心血管磁共振(CMR)成像的 HCM 患者。评估了所有 4 个心腔的功能,以及左心房(LA)和左心室(LV)的晚期钆增强(LGE),作为纤维化的指标。使用饱和脂肪的三维反转恢复准备快速失超梯度回波序列和图像强度比方法测量 LA-LGE;使用半自动阈值技术定量测量 LV-LGE。

结果

HCM 患者(n=45)根据 PAF 病史分为 2 组(PAF,无 AF)。所有 HCM 患者的 LA 后壁均有 LGE。PAF 组(n=18)的 LA 容积较大,LA 射血分数较低,整体峰值纵向 LA 应变(PLAS)较低,LA-LGE 较多,与无 AF 组(n=27)相比。LA 射血分数、PLAS 和 LA-LGE 之间呈适度负相关;LV-LGE 与 LA-LGE 之间呈正相关。与无 AF 组相比,PAF 组的 LV、右心房和右心室射血分数较低。

结论

PAF 与更大程度的结构 LA 重构和整体心肌病变相关,提示存在更严重的心脏 HCM 表型。

相似文献

1
Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging.心脏磁共振成像显示,肥厚型心肌病伴阵发性心房颤动患者左心房纤维化负担重。
JACC Clin Electrophysiol. 2019 Mar;5(3):364-375. doi: 10.1016/j.jacep.2018.10.016. Epub 2018 Dec 26.
2
CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.肥厚型心肌病合并心房颤动患者的心脏磁共振成像结果
J Cardiovasc Magn Reson. 2009 Sep 9;11(1):34. doi: 10.1186/1532-429X-11-34.
3
Left Atrial Performance in the Course of Hypertrophic Cardiomyopathy: Relation to Left Ventricular Hypertrophy and Fibrosis.肥厚型心肌病病程中的左心房功能:与左心室肥厚及纤维化的关系
Invest Radiol. 2017 Mar;52(3):177-185. doi: 10.1097/RLI.0000000000000326.
4
Left Atrial Mechanical Function and Global Strain in Hypertrophic Cardiomyopathy.肥厚型心肌病的左心房机械功能与整体应变
PLoS One. 2016 Jun 23;11(6):e0157433. doi: 10.1371/journal.pone.0157433. eCollection 2016.
5
Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.在肥厚型心肌病中,左心房纤维化与左心室心肌延迟强化程度及左心室应变相关。
Int J Cardiovasc Imaging. 2019 Jul;35(7):1309-1318. doi: 10.1007/s10554-019-01551-7. Epub 2019 Feb 21.
6
[The association between cardiac mr feature tracking strain and myocardial late gadolinium enhancement in patients with hypertrophic cardiomyopathy].肥厚型心肌病患者中心脏磁共振特征追踪应变与心肌延迟钆增强之间的关联
Kardiologiia. 2023 Feb 28;63(2):52-58. doi: 10.18087/cardio.2023.2.n2380.
7
Low Left Atrial Strain Is Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy Patients.左房应变率低值与肥厚型心肌病患者不良结局相关。
J Am Soc Echocardiogr. 2019 May;32(5):593-603.e1. doi: 10.1016/j.echo.2019.01.007. Epub 2019 Mar 20.
8
Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study.心房颤动患者左心房功能与左心房增强的相关性:心脏磁共振研究。
Circ Cardiovasc Imaging. 2015 Feb;8(2):e002769. doi: 10.1161/CIRCIMAGING.114.002769.
9
Evaluation of quantification methods for left arial late gadolinium enhancement based on different references in patients with atrial fibrillation.基于不同参考标准对心房颤动患者左心房晚期钆增强定量方法的评估
Int J Cardiovasc Imaging. 2015 Jun;31 Suppl 1:91-101. doi: 10.1007/s10554-014-0563-0. Epub 2014 Nov 4.
10
The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.肥厚型心肌病患者延迟钆增强磁共振与非持续室性心动过速负荷的关系:一项延迟对比增强磁共振研究。
J Cardiovasc Electrophysiol. 2019 May;30(5):651-657. doi: 10.1111/jce.13855. Epub 2019 Feb 2.

引用本文的文献

1
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy.肥厚型心肌病中的心房颤动与血栓栓塞风险
J Cardiovasc Imaging. 2025 Aug 25;33(1):12. doi: 10.1186/s44348-025-00057-2.
2
Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target.肥厚型心肌病中的心房重构与功能障碍:预后作用及治疗靶点
Front Cardiovasc Med. 2025 Jul 8;12:1620313. doi: 10.3389/fcvm.2025.1620313. eCollection 2025.
3
External validation of atrial fibrillation risk prediction tools in a racially diverse cohort of patients with hypertrophic cardiomyopathy.
肥厚型心肌病患者种族多样化队列中心房颤动风险预测工具的外部验证
Heart Rhythm. 2025 May 23. doi: 10.1016/j.hrthm.2025.05.046.
4
Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.肥厚型心肌病患者植入式心律转复除颤器的使用情况及预后的全球和时间趋势
Circ Arrhythm Electrophysiol. 2025 Feb;18(2):e013479. doi: 10.1161/CIRCEP.124.013479. Epub 2025 Feb 3.
5
Allele-specific dysregulation of lipid and energy metabolism in early-stage hypertrophic cardiomyopathy.早期肥厚型心肌病中脂质和能量代谢的等位基因特异性失调。
J Mol Cell Cardiol Plus. 2024 Jun;8. doi: 10.1016/j.jmccpl.2024.100073. Epub 2024 Mar 31.
6
Hybrid versus catheter ablation for Hypertrophic CardioMyopathy with Atrial Fibrillation (HCM-AF): study protocol for a randomised controlled trial.肥厚型心肌病伴心房颤动的杂交与导管消融治疗比较(HCM-AF):一项随机对照试验的研究方案。
BMJ Open. 2024 Oct 9;14(10):e089284. doi: 10.1136/bmjopen-2024-089284.
7
Gene therapy for atrial fibrillation.基因治疗心房颤动。
J Mol Cell Cardiol. 2024 Nov;196:84-93. doi: 10.1016/j.yjmcc.2024.09.004. Epub 2024 Sep 11.
8
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.肥厚型心肌病诊断与治疗指南 - 2024
Arq Bras Cardiol. 2024 Jul 26;121(7):e202400415. doi: 10.36660/abc.20240415.
9
The Role of Cardiovascular Magnetic Resonance Imaging in Patients with Cardiac Arrhythmias.心血管磁共振成像在心律失常患者中的作用。
Rev Cardiovasc Med. 2023 Sep 15;24(9):252. doi: 10.31083/j.rcm2409252. eCollection 2023 Sep.
10
Single-nucleus RNA/ATAC-seq in early-stage HCM models predicts SWI/SNF-activation in mutant-myocytes, and allele-specific differences in fibroblasts.早期肥厚型心肌病模型中的单核RNA/ATAC测序预测了突变心肌细胞中的SWI/SNF激活以及成纤维细胞中的等位基因特异性差异。
bioRxiv. 2024 Apr 24:2024.04.24.589078. doi: 10.1101/2024.04.24.589078.